Pioneering The Development of Novel Therapeutics Targeting Stress Support Pathways

Ribon is a clinical stage biopharmaceutical company pursuing the development of novel small molecules targeting stress support pathways in cancer and inflammation using our proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform.

Learn More

Our Proprietary BEACON+ Platform

We have created our proprietary BEACON+ to unlock the biochemical roles of NAD+-utilizing enzymes and to discover and develop novel small molecule therapeutics.

Learn More

RBN-2397 – PARP7 Inhibitor

Developing our lead product candidate, RBN-2397, as a potent, selective and orally available small molecule inhibitor of the monoPARP, PARP7, for the treatment of solid tumors.

Learn More
November 29

Cambridge, MA

Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim

Learn More
Join our team of experts.
Find Out More